Pfizer Pivots to Oncology to Offset Declining COVID-19 Revenue

Pfizer Inc. is undergoing a major strategic transition, pivoting away from its reliance on COVID-19 products toward a long-term focus on oncology, vaccines, and rare diseases. The pharmaceutical giant is now integrating obesity initiatives into its R&D pipeline as a potential future growth driver to diversify its portfolio. Additionally, ongoing cost-cutting initiatives are successfully improving profit margins, providing the company with greater financial flexibility. Financial analysts currently view the stock as undervalued, citing its robust dividend yield and the strategic integration of Seagen as key support factors. This shift is designed to mitigate the 'revenue cliff' caused by the sharp decline in demand for pandemic-era products like Paxlovid. While the transition remains complex, the combination of oncology leadership and improved operational efficiency is expected to drive long-term value.